Tanezumab, a non-opioid drug developed by Pfizer and Eli Lilly, met the main goals of a late-stage study in which over half of patients reported a significant reduction in hip or knee osteoarthritis pain.

Cara Therapeutics Inc said its arthritis drug met the main goal of reducing pain in patients in the first mid-stage study. The oral drug, CR845, was being evaluated in patients […]